| 5.23 0 (0.19%) | 04-29 11:16 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.65 | 1-year : | 7.26 |
| Resists | First : | 5.69 | Second : | 6.21 |
| Pivot price | 5.63 |
|||
| Supports | First : | 4.84 | Second : | 4.03 |
| MAs | MA(5) : | 5.67 |
MA(20) : | 5.57 |
| MA(100) : | 5.42 |
MA(250) : | 4.97 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 20.5 |
D(3) : | 48.7 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 10.07 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMRX ] has closed above bottom band by 8.5%. Bollinger Bands are 38.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.99 - 6.03 | 6.03 - 6.06 |
| Low: | 5.13 - 5.18 | 5.18 - 5.21 |
| Close: | 5.17 - 5.24 | 5.24 - 5.28 |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Tue, 21 Apr 2026
Immuneering brings 55-patient pancreatic survival update to ASCO oral - Stock Titan
Mon, 20 Apr 2026
Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification - Stock Titan
Fri, 17 Apr 2026
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fri, 10 Apr 2026
IMRX Options Chain — NASDAQ:IMRX - TradingView
Sat, 10 Jan 2026
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next - Yahoo Finance
Thu, 08 Jan 2026
Why Is Immuneering Stock Trading Lower Today? - Immuneering (NASDAQ:IMRX) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 17.8 (%) |
| Held by Institutions | 50.7 (%) |
| Shares Short | 10,300 (K) |
| Shares Short P.Month | 11,070 (K) |
| EPS | -1.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.1 % |
| Return on Equity (ttm) | -43.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -4.12 |
| PEG Ratio | 0 |
| Price to Book value | 1.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|